Navigation Links
BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Date:11/7/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 7 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the second of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

MINDSET-01 Trial

----------------

The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 in patients with relapsing-remitting MS. The fifteen month trial is fully enrolled with 218 patients at 24 sites in 6 countries. The objectives of the study are to demonstrate safety and efficacy of MBP8298 versus placebo as measured by relapse rate, MRI activity and disease progression.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Amnis Announces the Release of Multiple Upgrades to the ImageStream(R) System
5. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
6. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States
7. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
8. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... uBiome ... new insights on mechanics of fecal microbiota transplantation in C. difficile patients. , ... microbiome of patients undergoing fecal microbiota transplantation (FMT) as a treatment for Clostridium ...
(Date:6/30/2015)... ... ... The maximum number of shares proposed to be purchased in the tender offer ... stock). On June 29, 2015, the last trading day prior to the commencement of ... was $2.29 per share. , The tender offer will expire on July 28, 2015 ...
(Date:6/30/2015)... , June 30, 2015  Custom Computer Specialists, ... today that they are silver sponsors of the Primary ... PCDC sponsor, Custom is lending their support of PCDC,s ... communities. Since its founding in 1993, PCDC ... primary care area.  PCDC has financed over 100 completed ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... She has accepted the position of vice president of instruction at Chippewa Valley ... , “I greatly appreciated the opportunity to lead SIUE during the past three ...
Breaking Biology Technology:uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3
... Court for the Western District of Wisconsin has upheld ... , ,The Madison-based court affirmed the damage award to ... rejected Abbott Labs' request for a new trial on infringement. ... genotyping patent. Frank Morich, CEO of Innogenetics, said in a ...
... before I dashed off to finish my Christmas shopping, I ... focused on enterprise business intelligence , a sadly overlooked ... I think these prescient predictions from Nobby Akiha, senior vice ... in before too much of the New Year goes by. ...
... - A Middleton developer of pharmaceutical research tools ... two Wisconsin sources, Silicon Pastures and ... LLC , which was founded in 2002, will receive ... investors, and a minimum of $250,000 from Marshfield Investment ...
Cached Biology Technology:More enterprise software predictions for 2007 2More enterprise software predictions for 2007 3
(Date:6/26/2015)... -- ATL Technology, LLC, a top provider of electromechanical contract ... solutions, headquartered in Springville, Utah , has ... corporation with locations in Santa Clara, ... ). This acquisition will incorporate MedConx,s manufacturing ... Technology,s existing facility in Costa Rica , ...
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
(Date:6/24/2015)... Calif. , June 24, 2015  Synaptics ... of human interface solutions, today announced that Sharp ... to provide secure authentication for its latest flagship ... reached more than 200 million shipments of its ... Sharp reinforces Synaptics, strength, scalability and leadership in ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... exclusive license agreements to manufacture and sell novel reagents ... Techulon, Inc., a life sciences company, has signed ... to manufacture and sell novel transfection reagents used for ... cover a family of new molecules invented by Theresa ...
... A method pioneered to find the genetic basis of human ... traits in plants, according to a study published online March ... team led by biologists at the University of Southern California ... of genome-wide association (GWA) in a plant species. The study ...
... Osteoporosis Foundation (IOF) invites you to attend the ... the IOF Regionals: Asia-Pacific Osteoporosis Meeting, to be ... Mark your calendar: Online registration and abstract submission ... An exciting programme has been developed to ...
Cached Biology News:UC-developed technology to assist research and genetic drug delivery 2Searching for genes behind a trait 2Singapore program to provide clinical insight; showcase for regional research 2
...
Collected from sexually mature mice....
Sterile concentration of Dithiothreitol (DTT) solution in phosphate buffer (pH 7.0). Dilute contents in one vial (10- fold) to 100 ml. For use in liquefying sputum samples....
5 minutes from gel band to purified DNA...
Biology Products: